Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America

Study Overview
=================
Brief Summary
-----------------
The primary purpose of the study is to quantify participants' demographic parameters, country standard therapies, treatment patterns and outcomes among participants with chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) in oncology concentration hospitals in Latin America.

Detailed Description
-----------------
This is a retrospective (take a look back at events that already have taken place), non-interventional, multicenter (when more than one hospital or medical school team work on a medical research study) study to review medical records of adult participants with a diagnosis of CLL, MM or NHL anytime since 01 January 2006. Only data available from clinical practice will be collected. All eligible participants at participating centers will be included regardless of participant's demographics, prior or current treatments for disease, or clinical outcome. The period of observation will span from 01 January 2006 through present, but all eligible participants must be followed for a minimum of 1 year, unless the participant died within that first year. Participant demographic parameters, standard therapies, treatment patterns and outcomes will be primarily quantified.

Official Title
-----------------
Hemato-Oncology Latin America Observational Registry in CLL, Multiple Myeloma, Non-Hodgkin Lymphoma

Conditions
-----------------
Multiple Myeloma, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin

Intervention / Treatment
-----------------
* Other: Chronic Lymphocytic Leukemia (CLL)
* Other: Multiple Myeloma (MM)
* Other: Non-Hodgkin's lymphoma (NHL)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or non-Hodgkin lymphoma (NHL) anytime since January 1, 2006 At least one year of data following first observed diagnosis except in the case of the participant death within one year following first observed diagnosis Participant must sign a participation agreement/informed consent form (ICF) Exclusion Criteria: - Having one and only one consult in the center

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants with Chronic Lymphocytic Leukemia (CLL)<br>This is an observational study. Data will be captured for Participant's with diagnosis of Chronic Lymphocytic Leukemia according to hospital records in the questionnaire provided by the Sponsor. | Other: Chronic Lymphocytic Leukemia (CLL)<br>* This is observational study. Participants with Chronic Lymphocytic Leukemia (CLL) will be observed for 1 year.<br>|
| Participants with Multiple Myeloma (MM)<br>This is an observational study. Data will be captured for Participant's with diagnosis of Multiple Myeloma (MM) according to hospital records in the questionnaire provided by the Sponsor. | Other: Multiple Myeloma (MM)<br>* This is observational study. Participants with Multiple Myeloma (MM) will be observed for 1 year.<br>|
| Participants with Non-Hodgkin's lymphoma (NHL)<br>This is an observational study. Data will be captured for Participant's with diagnosis of non-Hodgkin's lymphoma (NHL) data according to hospital records in the questionnaire provided by the Sponsor. | Other: Non-Hodgkin's lymphoma (NHL)<br>* This is observational study. Participants with non-Hodgkin's lymphoma (NHL) will be observed for 1 year.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with Previous Comorbidities | Comorbidities included: heart, diabetes, hypertension, renal, infections, other neoplasia, neurologic, rheumatologic, HIV, thrombosis, bone and other. | 1 year | 
| Number of Participants as per treatment therapy received | Cancer treatment (Chronic Lymphocytic Leukemia [CLL], Multiple Myeloma [MM] and non-Hodgkin lymphoma [NHL]) for all participants is summarized by the number of participants who had any type of surgery or radiotherapy (external radiation or brachytherapy) or other drug treatments. | 1 year | 
| Overall survival | Overall Survival (OS) was defined as the time from date of starting treatment to death due to any cause. | 1 year | 
| Number of Participants with Response to Treatment | Number of participants who responded to treatment is presented. Treatment response will be assessed based on complete response or partial response. | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence Percentage of Participants with Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and non-Hodgkin lymphoma (NHL) | Incidence of CLL, MM and NHL will be reported. It is a percentage of the population at risk of developing the disease. | 1 year | 
| Prevalence Percentage of Participants with CLL, MM and NHL | Prevalence of CLL, MM and NHL will be reported. Prevalence will be estimated using available population demographic information as the denominators and using the percentage of registered participants with those cancers at the sites as the numerators. | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multiple Myeloma, chronic lymphocytic leukemia, Non-Hodgkin lymphoma